Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.8%

3 terminated/withdrawn out of 19 trials

Success Rate

82.4%

-4.2% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

43%

6 of 14 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

9(50.0%)

Phase 1

6(33.3%)

Phase 3

3(16.7%)

18Total

Phase 2(9)

Phase 1(6)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT03250338Phase 3Completed

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Role: lead

NCT03258931Phase 3Completed

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Role: lead

NCT03620318Unknown

Individual Patient Compassionate Use of Crenolanib

Role: lead

NCT02400281Phase 1Completed

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Role: lead

NCT02283177Phase 2Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Role: lead

NCT01522469Phase 2Completed

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Role: lead

NCT02626338Phase 1Completed

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Role: lead

NCT02400255Phase 2Completed

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Role: lead

NCT01657682Phase 2Completed

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Role: lead

NCT02847429Phase 3Unknown

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Role: lead

NCT02626364Phase 2Completed

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Role: lead

NCT03193918Phase 1Completed

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Role: lead

NCT03324243Phase 2Withdrawn

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Role: lead

NCT01229644Phase 2Terminated

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Role: lead

NCT01243346Phase 2Completed

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

Role: lead

NCT02270788Phase 1Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Role: collaborator

NCT01393912Phase 1Completed

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

Role: collaborator

NCT00386555Phase 2Withdrawn

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Role: lead

NCT00949624Phase 1Completed

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Role: lead

All 19 trials loaded